Tony Butler
Stock Analyst at Rodman & Renshaw
(0.56)
# 4,244
Out of 5,239 analysts
88
Total ratings
27.38%
Success rate
-22.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tony Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Initiates: Buy | $25 | $9.81 | +154.84% | 2 | Dec 20, 2024 | |
| HURA TuHURA Biosciences | Initiates: Buy | $11 | $2.42 | +354.55% | 1 | Dec 19, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $18 | $1.58 | +1,039.24% | 4 | Sep 26, 2024 | |
| IPSC Century Therapeutics | Reiterates: Buy | $16 | $2.29 | +598.69% | 5 | Aug 10, 2023 | |
| FATE Fate Therapeutics | Reiterates: Buy | $10 | $2.25 | +344.44% | 4 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Buy | $75 | $52.83 | +41.96% | 8 | Aug 8, 2023 | |
| GTBP GT Biopharma | Reiterates: Hold | $60 | $0.32 | +18,498.88% | 5 | Aug 7, 2023 | |
| CGEN Compugen | Reiterates: Buy | $13 | $2.83 | +359.36% | 6 | Aug 7, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $50 | $4.72 | +959.32% | 5 | Aug 3, 2023 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $15 | $2.30 | +552.17% | 8 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1,250 | $4.54 | +27,433.04% | 6 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $2.60 | +476.92% | 1 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.19 | +740.34% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $0.63 | +2,597.56% | 2 | Jul 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8.3 → $166 | $3.44 | +4,725.58% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $4.09 | +1,366.99% | 4 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.60 | +14,900.00% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $120 | $2.32 | +5,072.41% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $360 | $0.34 | +105,907.07% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $5 → $2 | $1.45 | +37.93% | 6 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.61 | +2,346.98% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $10 | $1.44 | +594.44% | 2 | Feb 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.87 | +702.14% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $110 | $13.99 | +686.28% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $960 | $9.78 | +9,715.95% | 1 | Mar 2, 2020 |
Atara Biotherapeutics
Dec 20, 2024
Initiates: Buy
Price Target: $25
Current: $9.81
Upside: +154.84%
TuHURA Biosciences
Dec 19, 2024
Initiates: Buy
Price Target: $11
Current: $2.42
Upside: +354.55%
Biomea Fusion
Sep 26, 2024
Upgrades: Buy
Price Target: $18
Current: $1.58
Upside: +1,039.24%
Century Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $16
Current: $2.29
Upside: +598.69%
Fate Therapeutics
Aug 9, 2023
Reiterates: Buy
Price Target: $10
Current: $2.25
Upside: +344.44%
CRISPR Therapeutics AG
Aug 8, 2023
Reiterates: Buy
Price Target: $75
Current: $52.83
Upside: +41.96%
GT Biopharma
Aug 7, 2023
Reiterates: Hold
Price Target: $60
Current: $0.32
Upside: +18,498.88%
Compugen
Aug 7, 2023
Reiterates: Buy
Price Target: $13
Current: $2.83
Upside: +359.36%
Bicycle Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $50
Current: $4.72
Upside: +959.32%
Allogene Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $15
Current: $2.30
Upside: +552.17%
Aug 2, 2023
Reiterates: Buy
Price Target: $1,250
Current: $4.54
Upside: +27,433.04%
Jul 31, 2023
Initiates: Buy
Price Target: $15
Current: $2.60
Upside: +476.92%
Jul 12, 2023
Reiterates: Buy
Price Target: $10
Current: $1.19
Upside: +740.34%
Jul 7, 2023
Reiterates: Buy
Price Target: $17
Current: $0.63
Upside: +2,597.56%
Jul 3, 2023
Reiterates: Buy
Price Target: $8.3 → $166
Current: $3.44
Upside: +4,725.58%
Jun 7, 2023
Reiterates: Buy
Price Target: $60
Current: $4.09
Upside: +1,366.99%
Jun 5, 2023
Reiterates: Buy
Price Target: $240
Current: $1.60
Upside: +14,900.00%
Jun 1, 2023
Assumes: Buy
Price Target: $120
Current: $2.32
Upside: +5,072.41%
Jun 1, 2023
Assumes: Buy
Price Target: $360
Current: $0.34
Upside: +105,907.07%
May 30, 2023
Maintains: Hold
Price Target: $5 → $2
Current: $1.45
Upside: +37.93%
Jan 5, 2023
Initiates: Buy
Price Target: $15
Current: $0.61
Upside: +2,346.98%
Feb 17, 2022
Downgrades: Neutral
Price Target: $30 → $10
Current: $1.44
Upside: +594.44%
Nov 19, 2021
Initiates: Buy
Price Target: $15
Current: $1.87
Upside: +702.14%
Jun 28, 2021
Maintains: Buy
Price Target: $80 → $110
Current: $13.99
Upside: +686.28%
Mar 2, 2020
Initiates: Buy
Price Target: $960
Current: $9.78
Upside: +9,715.95%